NASDAQ:PCRX Pacira BioSciences Q3 2026 Earnings Date & Estimates $36.39 +11.19 (+44.40%) Closing price 04:00 PM EasternExtended Trading$36.34 -0.05 (-0.12%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Pacira BioSciences is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Pacira BioSciences in Q3 2026Pacira BioSciences is expected to post earnings of $0.73 per share on revenue of $183.04 million. In the same quarter a year earlier Pacira BioSciences reported $0.70 per share on revenue of $179.52 million. Pacira BioSciences last reported on August 4, 2026, posting $0.73 per share and beating the $0.65 consensus estimate. Pacira BioSciences has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.73Expected Revenue$183.04 millionPrior-Year EPS$0.70Prior-Year Revenue$179.52 millionExpected EPS Growth+4.7%Expected Revenue Growth+2.0%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.73 (Beat by +$0.08)Last Quarter Revenue$192.40 millionEPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Pacira BioSciences Q3 2026 Earnings FAQ When does Pacira BioSciences report Q3 2026 earnings? Pacira BioSciences (NASDAQ:PCRX) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. What time is Pacira BioSciences' Q3 2026 earnings call? Pacira BioSciences' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Pacira BioSciences? Analysts expect Pacira BioSciences to post earnings of $0.73 per share for Q3 2026. How much revenue is Pacira BioSciences expected to report? The consensus revenue estimate for Pacira BioSciences is $183.04 million for Q3 2026. Pacira BioSciences Earnings HeadlinesViatris Agrees To Acquire Pacira BioSciences In $1.65 Bln Cash Deal2 hours ago | rttnews.comHAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?2 hours ago | finance.yahoo.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 8 at 1:00 AM | Porter & Company (Ad)Viatris agrees to acquire Pacira BioSciences for $1.65 billion in non-opioid pain therapy expansion2 hours ago | msn.comViatris Agrees to Acquire Pacira BioSciences in $1.65 Billion Deal2 hours ago | finance.yahoo.comViatris to buy Pacira BioSciences in $1.65B deal2 hours ago | msn.comSee More Pacira BioSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pacira BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pacira BioSciences and other key companies, straight to your email. Email Address About Pacira BioSciencesPacira BioSciences (NASDAQ:PCRX) is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies. Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief. Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies. Pacira primarily serves healthcare professionals and institutions in the United States and has pursued international commercialization through partnerships and licensing arrangements.View Pacira BioSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
